Aimmune Therapeutics, a biopharmaceutical company developing a peanut allergy treatment, has presented data on its phase two trials of a new treatment option and the biomarkers it may prove.
The company shared its findings at the annual Food Allergy Research and Education (FARE) Research Retreat, which is held by the research foundation to discuss the latest findings in allergy research. Aimmune’s latest round of studies included 55 patients, 27 of which were shown to have the biomarkers Aimmune targets as being peanut allergy indicators.
Of the patients, all emerged from the trial without reactions to the food challenge when the study completed.
“If replicated in our ongoing Phase 3 PALISADE trial, we believe that these findings could have very positive implications for the adoption of AR101 in clinical practice,” continued Dr. Dilly. “According to the published scientific literature, at least 80 percent of untreated people with peanut allergy have psIgE levels below 100 kUA/l, and, importantly, there seems to be no clear correlation between psIgE levels and reaction threshold or severity of reaction.”
At the FARE retreat, another unrelated presentation was given regarding the peanut-specific allergy biomarkers. A similar study of patients receiving active peanut allergy sensitization treatment showed a dropping of those markers to coincide with tolerance increases.